Three Rivers Pharmaceuticals(R), LLC Obtains Additional Commercial Rights to Infergen(R) From Amgen Inc.
Posted on: Wednesday, 17 September 2008, 03:00 CDT
CRANBERRY TOWNSHIP, Pa., Sept. 17 /PRNewswire/ -- Three Rivers Pharmaceuticals, LLC announced today that it has signed a definitive license agreement with Amgen Inc. to expand its commercial rights to the hepatitis C drug Infergen. Three Rivers Pharmaceuticals will obtain commercial rights to Infergen in all markets except Japan. In addition, Three Rivers Pharmaceuticals will obtain commercial rights to China effective March 31, 2009. Three Rivers Pharmaceuticals currently has commercial rights to Infergen in the United States and Canada.
"The expansion of commercial rights to Infergen compliments Three Rivers Pharmaceuticals strategy to continue to grow its hepatitis C franchise," stated Patrick Kerrish RPh., MBA Three Rivers Pharmaceuticals' Executive Vice President of Business Development.
Three Rivers Pharmaceuticals will seek marketing partners to assist with the commercialization of Infergen outside of the United States. Interested marketing partners should contact Patrick Kerrish at pkerrish@3riverspharma.com .
Infergen, or consensus interferon, is a unique, bio-optimized, selective and highly potent type 1 interferon alpha originally developed by Amgen and launched in the United States in 1997. Infergen is indicated for the treatment of chronic HCV infection in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and /or the presence of HCV RNA.
Important Safety Information
Physicians and patients can obtain additional prescribing information regarding Infergen, including the product's safety profile and the box warning for all interferon alphas regarding neuropsychiatric, autoimmune, ischemic and infectious disorders, by visiting http://www.infergen.com/ .
About Three Rivers Pharmaceuticals
Three Rivers Pharmaceuticals is a privately held company headquartered in Cranberry Township, Pennsylvania that focuses on specialized therapies including hepatitis C therapies. With its unique experience and understanding of the complex challenges of treating chronic, difficult diseases, Three Rivers is a valuable partner in the healthcare community.
The company's mission is to develop, manufacture, and market the highest quality branded and generic drug products for patients with serious diseases. Three Rivers Pharmaceuticals focuses on the specialized therapies because of its extensive knowledge and experience in this area. More information about the company can be found at http://www.3riverspharma.com/ .
Three Rivers Pharmaceuticals, LLC
CONTACT: Patrick Kerrish of Three Rivers Pharmaceuticals,+1-724-778-6013, pkerrish@3riverspharma.com
Web site: http://www.3riverspharma.com/http://www.infergen.com/
Source: PRNewswire
Related Articles
- Three Rivers Pharmaceuticals Signs Licensing Agreement With Amgen
- Valeant Pharmaceuticals Completes Divestment of Hep-C Drug Infergen(R) to Three Rivers Pharmaceuticals(R), LLC
- Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) From Valeant Pharmaceuticals
- Valeant Pharmaceuticals Sells Hep-C Drug Infergen(R) to Three Rivers Pharmaceuticals(R), LLC for $91 Million
- Three Rivers Pharmaceuticals, LLC Protects Its Intellectual Property
- Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (Lisdexamfetamine Dimesylate) As a Novel Treatment for ADHD
- New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD
- New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104
- New River Pharmaceuticals Announces Exercise of Co-Promotion Option in the U.S. For NRP104
 |
 |
User Comments (0)
RSS Feeds